Cristóbal Belda-Iniesta

ORCID: 0000-0003-3254-7492
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Chromatin Remodeling and Cancer
  • Fibroblast Growth Factor Research
  • Sarcoma Diagnosis and Treatment
  • Glioma Diagnosis and Treatment
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Cancer, Hypoxia, and Metabolism
  • Colorectal Cancer Surgical Treatments
  • Cancer Treatment and Pharmacology
  • Genetic factors in colorectal cancer
  • SARS-CoV-2 and COVID-19 Research
  • Gastric Cancer Management and Outcomes
  • Colorectal and Anal Carcinomas
  • Cancer Cells and Metastasis
  • MicroRNA in disease regulation
  • Health Systems, Economic Evaluations, Quality of Life
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Lung Cancer Diagnosis and Treatment
  • Epigenetics and DNA Methylation
  • RNA modifications and cancer
  • Economic and Financial Impacts of Cancer
  • PI3K/AKT/mTOR signaling in cancer
  • Extracellular vesicles in disease

Instituto de Salud Carlos III
2014-2024

Hospital Universitario Infanta Sofía
2009-2023

Hospital Universitario HM Sanchinarro
2012-2022

Escuela Nacional de Sanidad
2014-2021

Centro Nacional de Microbiologia
2021

HM Hospitales
2014-2020

Ministerio de Ciencia, Innovación y Universidades
2020

Henry Ford Hospital
2017

University of Zurich
2017

Centro Oncológico de Galicia
2012-2016

Marina Chiara Garassino Byoung Chul Cho Joo-Hang Kim Julien Mazières Johan Vansteenkiste and 95 more H. Léna Jesus Corral Jaime Jhanelle E. Gray John D. Powderly C. Chouaïd Paolo Bidoli Paul Wheatley‐Price Keunchil Park Ross A. Soo Yifan Huang Catherine Wadsworth Phillip A. Dennis Naiyer A. Rizvi Luis Paz-Ares Rodríguez Silvia Novello Sandrine Hiret Peter Schmid Eckart Laack Raffaele Califano Makoto Maemondo Sang‐We Kim Jamie E. Chaft David Vicente Baz Thierry Berghmans Dong‐Wan Kim Veerle Surmont Martin Reck Ji‐Youn Han Esther Holgado Martin Cristóbal Belda-Iniesta Yuichiro Oe Antonio Chella Akhil Chopra G. Robinet Héctor Soto Parrà Michael J. Thomas Parneet Cheema Nobuyuki Katakami Wu‐Chou Su Young‐Chul Kim Juergen Wolf Jong-Seok Lee Hideo Saka Michele Stanislaw Milella Inmaculada Ramos García Anne Sibille Takashi Yokoi Eun Joo Kang Shinji Atagi E. Spaeth-Schwalbe Makoto Nishio Fumio Imamura Nashat Gabrail R. Veillon Sofie Derijcke Tadashi Maeda Dylan M. Zylla Kendra Kubiak Armando Santoro Ma. Noemi Uy Sarayut Lucien Geater Antoîne Italiano Dariusz M. Kowalski Fabrice Barlési Yuh‐Min Chen David R. Spigel Busyamas Chewaskulyong Ramón García Gómez Rosa Álvarez James Chih‐Hsin Yang Te‐Chun Hsia Fabrice Denis Hiroshi Sakai Mark Vincent Kōichi Goto Joaquim Bosch‐Barrera Glen J. Weiss Jean-Luc Canon Christian W. Scholz Massimo Aglietta Hirotsugu Kemmotsu Koichi Azuma Penelope A. Bradbury Ronald Feld Abraham Chachoua Jacek Jassem Rosalyn A. Juergens Ramón Palmero Albert Malcolm Nandagopal Vrindavanam Kaoru Kubota Cornelius F. Waller David Waterhouse Bruno Coudert Z. Mark

10.1016/s1470-2045(18)30144-x article EN The Lancet Oncology 2018-03-12
Alberto M. Borobia Antonio J. Carcas Mayte Pérez‐Olmeda Luís Castaño María Jesús Bertrán and 95 more Javier García‐Pérez M. Josefa Campins Antonio Portolés María González-Pérez Maria Teresa García Morales Eunate Arana‐Arri Marta Aldea Francisco Díez‐Fuertes Inmaculada Fuentes-Durá Ana Ascaso David Lora Natale Imaz-Ayo Lourdes E. Barón-Mira Antònia Agustí Carla Pérez-Ingidua Agustı́n Gómez de la Cámara José Ramón Arribas Jordi Ochando José Alcamı́ Cristóbal Belda-Iniesta Jesús Frías Lucía Martínez de Soto Amelia Rodríguez Mariblanca Lucía Díaz García Elena Ramı́rez Enrique Seco Meseguer Stefan Stewart Alicia Marín Candón Irene García-García Mikel Urroz Jaime Monserrat Villatoro Paula de la Rosa Marta Sanz García Cristina López Crespo Vega Mauleón Martínez Raquel de Madariaga Castell Laura Vitón Vara Julio García‐Rodríguez Antonio Buño Soto Eduardo López Granados Carmen Cámara Esther Rey Cuevas Pilar Ayllon García María Jiménez-González Victoria Hernández Rubio Paloma Moraga Alapont Amparo Rodríguez Sánchez Rocío Prieto Silvia Llorente Gómez Cristina Miragall Roig Marina Aparicio Marlasca Fernando Calle Marta Arsuaga B. Duque Susana Meijide Aitor García de Vicuña Ana Santorcuato Iraide Expósito Sara Benito Joseba Andia Cristina Castillo Esther Irurzun Jesús Camino Mikel Temprano Josune Goikoetxea Alazne Bustinza Maialen Larrea Mikel Gallego Dolores García-Vázquez Ana B. de la Hoz Gustavo Pérez de Nanclares Estíbaliz Pérez-Guzmán Eneko Idoyaga Adriana Lamela Jesús Oteo María Castillo de la Osa Lourdes Hernández Gutiérrez María Elena Andrés Galván Esther Calonge María Elena Andrés Galván Mercedes Bermejo Humberto Erick de la Torre-Tarazona Almudena Cascajero Giovanni Fedele Concepción Perea Isabel Cervera Irene Bodega‐Mayor María Montes‐Casado Pilàr Portolés Jana Baranda Laura Granés Sulayman Lazaar Sara Herranz María Eugènia Mellado Marta Tortajada

BackgroundTo date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK).MethodsWe did a phase 2, open-label, randomised, controlled trial adults aged 18–60 years, vaccinated single 8–12 weeks before screening, history SARS-CoV-2 infection....

10.1016/s0140-6736(21)01420-3 article EN other-oa The Lancet 2021-06-25

Tumor-cell-secreted extracellular vesicles (EVs) can cross the disrupted blood-brain barrier (BBB) into bloodstream. However, in certain gliomas, BBB remains intact, which might limit EVs release. To evaluate ability of tumor-derived to BBB, we used an orthotopic xenotransplant mouse model human glioma-cancer stem cells featuring intact BBB. We demonstrated that all types tumor cells-derived EVs-apoptotic bodies, shedding microvesicles and exosomes-cross be detected peripheral blood,...

10.18632/oncotarget.13635 article EN Oncotarget 2016-11-26

The aim of this study was to investigate selected proteomic markers the metabolic phenotype breast carcinomas as prognostic cancer progression. For purpose, a series 101 and 13 uninvolved samples were examined for quantitative differences in protein expression mitochondrial glycolytic markers. β-subunit H + -ATP synthase (β-F1-ATPase) heat shock 60 (Hsp60), glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase lactate dehydrogenase identified by immunological techniques. Correlations...

10.1093/carcin/bgi188 article EN Carcinogenesis 2005-07-20

KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy patients with metastatic cancer, and thus represent a true indicator of EGFR pathway activation status.KRAS were retrospectively studied using polymerase chain reactions subsequent sequencing codons 12 13 (exon 2) 110 tumors. These studies performed tissue samples from both the tumor their related metastases (93 liver, 84%; 17 lung, 16%). All...

10.1371/journal.pone.0008199 article EN cc-by PLoS ONE 2009-12-18

Iron oxide nanoparticles (IONPs) occupy a privileged position among magnetic nanomaterials with potential applications in medicine and biology. They have been widely used preclinical experiments for imaging contrast enhancement, resonance, immunoassays, cell tracking, tissue repair, hyperthermia drug delivery. Despite these promising results, their successful translation into clinical setting is strongly dependent upon physicochemical properties, toxicity functionalization possibilities....

10.5772/58841 article EN cc-by Nanobiomedicine 2014-01-01

Purpose Bevacizumab regimens are approved for the treatment of recurrent glioblastoma in many countries. Aberrant mesenchymal-epithelial transition factor (MET) expression has been reported and may contribute to bevacizumab resistance. The phase II study GO27819 investigated monovalent MET inhibitor onartuzumab plus (Ona + Bev) versus placebo (Pla glioblastoma. Methods At first recurrence after chemoradiation, bevacizumab-naïve patients with were randomly assigned 1:1 receive Ona (15 mg/kg,...

10.1200/jco.2015.64.7685 article EN Journal of Clinical Oncology 2017-01-20

Extracellular vesicles (EVs) are small membrane-bound which play an important role in cell-to-cell communication. Their molecular cargo analysis is presented as a new source for biomarker detection, and it might provide alternative to traditional solid biopsies. However, the most effective approach EV isolation not yet well established.

10.1186/s12967-019-1825-3 article EN cc-by Journal of Translational Medicine 2019-03-11

FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study selective FGFR1-3 inhibitor, infigratinib (BGJ398), patients with FGFR-altered recurrent gliomas.Adults recurrent/progressive gliomas harboring received oral 125 mg on days 1 to 21 28-day cycles. The primary endpoint was investigator-assessed 6-month progression-free survival (PFS) rate by Response...

10.1158/1078-0432.ccr-21-2664 article EN cc-by-nc-nd Clinical Cancer Research 2022-03-28

Abstract Lung cancer is the top cause of cancer‐related deceases. One reasons development resistance to chemotherapy treatment. In particular, stem cells ( CSC s), can escape treatment and regenerate bulk tumor. this article, we describe a comparison between resistant cisplatin s, both derived from non‐small‐cell lung cell lines H460 A549. Cisplatin‐resistant were obtained after single with drug. s isolated by culture in defined media, under nonadherent conditions. The clonogenic, could be...

10.1002/cam4.291 article EN Cancer Medicine 2014-06-25

One of the major limitations associated with platinum use is resistance that almost invariably develops in different tumor types.In current study, we sought to identify epigenetically regulated microRNAs as novel biomarkers lung and ovarian cancers, ones highest ratios chemo-resistance.Methods: We combined transcriptomic data from microRNA mRNA under influence an epigenetic reactivation treatment a panel four paired cisplatin -sensitive -resistant cell lines, followed by real-time expression...

10.7150/thno.20112 article EN cc-by Theranostics 2017-01-01

Obstructive sleep apnoea (OSA) is associated with cancer incidence and mortality. The contribution of the immune system appears to be crucial; however, potential role monocytes natural killer (NK) cells remains unclear. Quantitative reverse transcriptase PCR, flow cytometry in vitro assays were used analyse phenotype response activity 92 patients OSA (60 recently diagnosed untreated 32 after 6 months treatment continuous positive airway pressure (CPAP)) 29 healthy volunteers (HV). We...

10.1183/13993003.02456-2016 article EN European Respiratory Journal 2017-06-01

Health information grows exponentially (doubling every 5 years), thus generating a sort of inflation science, i.e. the generation more knowledge than we can leverage.In an unprecedented data-driven shift, today doctors have no longer time to keep updated.This fact explains why only one in five medical decisions is based strictly on evidence, which inevitably leads variability.A good solution lies clinical decision support systems, big data analysis.As processing large amounts gains...

10.9781/ijimai.2017.03.001 article EN cc-by International Journal of Interactive Multimedia and Artificial Intelligence 2017-03-18
Coming Soon ...